Natco Pharma (NATCOPHARM.NS) Osake Kurssi
Natco Pharma Kurssi
Viimeisten 19 vuoden aikana Natco Pharman liikevaihto kasvoi 16,0 % vuodessa ja ylsi 40,78 Mrd. INR:een. Osakekohtainen tulos on kasvanut 22,4 % vuodessa viimeisten 19 vuoden aikana. Natco Pharman nettomarginaali 34,8 % on noussut verrattuna 8,7 %:iin muutama vuosi sitten. Nykyhinnalla osinkotuotto on noin 0,64 %. Jakosuhde on noin 12 % tuloksesta. Osinko on kasvanut 17,1 % vuodessa viimeisten 19 vuoden aikana. Natco Pharman 12 kuukauden konsensustavoitehinta on 930,75 INR, noin yli kurssia 18,5 %. 16 analyytikosta 3 suosittaa ostoa — kokonaiskonsensus on Myy.
Natco Pharma osakekurssi
Hae nämä tiedot Eulerpool API:n kautta
100 000 pyyntöä/kk ilmaiseksi · ei luottokorttia
Natco Pharma liiketoimintamalli ja osakeanalyysi
Usein kysytyt kysymykset Natco Pharma -osakkeesta
Natco Pharma Ltd is an Indian pharmaceutical company with a well-defined business model. The company primarily focuses on the development, manufacturing, and marketing of a wide range of generic pharmaceutical products. It has a strong presence in both domestic and international markets, supplying affordable and high-quality medicines. Natco Pharma follows a vertically integrated business approach, encompassing the entire pharmaceutical value chain, including R&D, API manufacturing, formulation development, and marketing. By consistently delivering innovative pharmaceutical solutions, Natco Pharma aims to fulfill the healthcare needs of patients worldwide while ensuring sustainable growth and profitability.
Natco Pharma Ltd is primarily active in the pharmaceutical industry.
The main competitors of Natco Pharma Ltd in the market include Sun Pharmaceutical Industries Ltd, Dr. Reddy's Laboratories Ltd, Lupin Limited, Cipla Limited, and Glenmark Pharmaceuticals Ltd.
Natco Pharma Ltd is an Indian pharmaceutical company with a rich history and background. Founded in 1981, the company has emerged as a leading player in the global pharmaceutical industry. Natco Pharma specializes in developing, manufacturing, and marketing generic pharmaceuticals, active pharmaceutical ingredients (APIs), and biologics. With a strong focus on research and development, the company has a diverse product portfolio across multiple therapeutic areas, including oncology, cardiology, gastroenterology, and more. Natco Pharma Ltd is known for its commitment to quality, affordability, and accessibility of healthcare products, making it a trusted name in the pharmaceutical sector.
Natco Pharma Ltd has achieved several significant milestones over the years. Firstly, the company received approval for its first ANDA from the US FDA in 2003, marking a major breakthrough in its international presence. In 2012, Natco Pharma Ltd entered into a landmark agreement with a leading pharmaceutical company to manufacture and market a generic version of a widely prescribed anticancer drug, showcasing its expertise in the oncology segment. Furthermore, the company has filed multiple Abbreviated New Drug Applications (ANDAs) and received several approvals, strengthening its product portfolio. With its consistent focus on innovation, quality, and expanding global reach, Natco Pharma Ltd continues to achieve remarkable milestones in the pharmaceutical industry.
Natco Pharma Ltd is primarily present in multiple countries and regions worldwide. With a strong global footprint, the company operates across countries like the United States, Canada, Europe, Australia, South Africa, and various Asian countries. Natco Pharma Ltd has established a significant presence in these markets, leveraging its expertise in pharmaceutical research, development, and marketing. With its continuous efforts towards expanding its international operations, the company aims to serve diverse patient populations and healthcare needs globally.
The values and corporate philosophy of Natco Pharma Ltd are centered around innovation, excellence, and ethical business practices. Natco Pharma is committed to providing high-quality pharmaceutical products and services that improve the health and well-being of individuals. The company is known for its dedication to research and development, striving to develop cutting-edge medicines and therapies that address unmet medical needs. Natco Pharma also prioritizes sustainability and social responsibility, aiming to contribute positively to society and the environment. With their strong emphasis on integrity and customer satisfaction, Natco Pharma Ltd continues to establish itself as a trusted and reliable player in the pharmaceutical industry.
Analyytikot asettavat tällä hetkellä Natco Pharma-osakkeelle keskimääräisen tavoitehinnan 924,22 INR (mediaani: 930,75 INR), mikä merkitsee +17,7 % viimeisimpään hintaan verrattuna. Konsensus perustuu 16 analyytikkoarvioon.
16 analyytikkoa arvioi tällä hetkellä Natco Pharma-osaketta: 3 suosittaa ostoa, 4 pitoa ja 9 myyntiä.
Nykyisellä valuuttakurssilla Natco Pharma-osake noteerataan hintaan 7,40 EUR (785,40 INR).
Natco Pharma-osake (NATCOPHARM.NS) on listattuna 2 pörssissä, muun muassa: NSE (Indien) (NATCOPHARM.NS).
Natco Pharma Ltd is a multinational company specializing in the development, manufacturing, and marketing of medications. With its headquarters in Hyderabad, India, they distribute their products worldwide in over 40 countries and continue to grow. The company operates in various sectors, including oncology products, active pharmaceutical ingredients (API), nucleosides, generics, and bioequivalents. Oncology products are their main sector, where Natco holds a significant market position. Through intensive research and development, Natco Pharma has developed a variety of medications to provide necessary protection and treatment for cancer patients. In addition, Natco has developed a wide range of API products. With over 200 APIs, Natco is one of the leading companies in India in this field. Production also includes more than 70 generic medications developed as cost-effective solutions for the treatment of various diseases. Another business area is the production of nucleosides, which are a group of organic compounds involved in the formation of nucleic acids in the human body. These products are used in HIV treatment. Furthermore, Natco Pharma also offers bioequivalents. These products are developed and manufactured in the same way as the original product and have the same efficacy and safety. Bioequivalents often replace expensive original products, resulting in cost savings for patients. Overall, Natco Pharma's business model is designed for self-sustainability. This means that they are self-funded and operate independently from other investors. The products are very affordable while maintaining a high quality standard. Through global distribution, Natco becomes an important company in many areas of medicine. The financial structure of the company is based on a broad revenue base. This means that the company does not rely on a single product but instead offers multiple products in different markets. This minimizes risk and provides more solid and reliable revenue forecasts. Additionally, Natco has a portfolio of affordable and effective bioequivalents and generics. This has given the company a significant market position in many countries. The company emphasizes strong and independent production, allowing for flexibility in product and service offerings. As a whole, the company's concept is focused on diversity. Through its strong presence in cancer-related products and generic alternatives, Natco Pharma Ltd has strengthened its global standing. The company also relies on its research and development department, which constantly works on new products.
liikevaihto Natco Pharma on 40,78 Mrd. INR. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.
voitto Natco Pharma on 14,19 Mrd. INR. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.
Natco Pharma:n hinta-voitto-suhde (P/E) on tällä hetkellä 9,92. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan Natco Pharma-osakkeen arvostusta.
Natco Pharma:n hinta-myynti-suhde (P/S) on tällä hetkellä 3,45. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii Natco Pharma-osakkeen arvostuskennuslukuna.
Natco Pharma:n Eulpool-laatuscore on 7/10.
Natco Pharma:n ISIN on INE987B01026. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.
Natco Pharma:n ticker on NATCOPHARM.NS. Tämä pörssinoteeraus käytetään Natco Pharma-osakkeiden kauppaan pörssissä.
Natco Pharma osake
Natco Pharma vertaisryhmä
Natco Pharma Ticker
Natco Pharma FIGI
Kaikki tunnusluvut ja syvällinen analyysi Natco Pharma:sta
Meidän osakeanalyysimme Natco Pharma-osakkeesta sisältää tärkeitä taloudellisia tunnuslukuja, kuten liikevaihdon, voiton, P/E-luvun, P/S-luvun, EBIT:n sekä tietoja osingosta. Lisäksi tarkastelemme asioita kuten osakkeet, markkina-arvo, velat, oma pääoma ja vastuut Natco Pharma:n yhteydessä. Jos etsit yksityiskohtaisempaa tietoa näistä aiheista, tarjoamme alisivuillamme kattavia analyysejä: